Oppenheimer maintains Legend Biotech at Perform, lowers price target to $25 from $40

Oppenheimer kept its 'Perform' rating on Legend Biotech but cut its price target to $25 from $40, a 37.5% reduction. This implies a 22.5% upside from the Nov 10 close of $20.41. Other recent analyst targets for the company range from $43 to $61.

Original reporting
Published Nov 11, 2026, 5:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 6:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Oppenheimer maintains Legend Biotech at Perform, lowers price target to $25 from $40 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The 37.5% target reduction reflects heightened risk perception, potentially triggering short‑term sell‑offs.

02

Market read

Target cut is the primary new information, offering a modest trading edge for short‑term positions.

03

What to watch

Upcoming clinical trial data or partnership announcements could offset the target reduction.

Relevance 5/10Novelty 5/10Timing: immediate today

Background

Legend Biotech (LGND) is a Nasdaq‑listed biotech focused on oncology therapies. Analyst coverage is limited, making target changes a notable signal.

Market effects

May weigh on other small‑cap biotech stocks as analysts reassess sector risk.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Some investors may view the cut as an overreaction and see buying opportunity if pipeline progress remains unchanged.

Key entities

  • Oppenheimer

    Equity research firm that issued the target cut.

  • Legend Biotech

    Biotech firm developing oncology treatments.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.